Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtct.2024.12.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phospholipid-Rich DC-Vesicles with Preserved Immune Fingerprints: A Stable and Scalable Platform for Precision Immunotherapy.
Biomedicines
May 2025
Department of Oncopathology, OGRD Alliance, Lewes, DE 19958, USA.
Despite the progress in cancer immunotherapy, therapeutic responses in solid tumors remain suboptimal due to the immunosuppressive nature of the tumor microenvironment (TME), limited immune cell infiltration, and inefficient delivery of immune-activating agents. Dendritic cell-based therapies possess strong immunological potential but face challenges in viability, standardization, and scalability. Likewise, exosomes and CAR-T cells are hindered by instability, production complexity, and limited efficacy in immune-excluded tumor settings.
View Article and Find Full Text PDFInsights from the bottom-up development of LGR5-targeting immunotherapeutics.
Immunother Adv
April 2025
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, United Kingdom.
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a transcriptional target gene of the Wnt signalling pathway, is overexpressed in multiple cancers, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pre-B acute lymphoblastic leukaemia (pre-B ALL) and has emerged as a promising therapeutic target. Here, we reflect on the bottom-up development of a novel α-LGR5 therapeutic antibody we have recently reported, into a palette of LGR5-targeting immunotherapeutic modalities: antibody-drug conjugates (ADCs), bispecific T cell engagers (bispecific engagers), and chimeric antigen receptor (CAR) T cells. The α-LGR5 antibody is highly specific and accurately detects LGR5 protein expression levels, enabling its use as a prognostic biomarker for identifying LGR5 tumour types.
View Article and Find Full Text PDFThe bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis.
Transplant Cell Ther
January 2025
National Centre for Infectious in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Austral
Roadmap to next-generation cancer vaccines.
J Control Release
July 2022
College of Pharmaceutical Sciences, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China; Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and, Materials Science, Soochow University, Suzhou 215123, PR China. Electronic addre
Cancer vaccines have emerged as powerful and clinically viable therapeutic modalities to reduce tumor burden, eradicate residual cancer cells and prevent relapse. The past years have witnessed rapid advances in various scientific and engineering approaches to next-generation cancer vaccines. This perspective highlights the cutting-edge technologies to elicit robust, durable and cancer-specific immune responses as well as interesting research directions in augmenting the therapeutic efficacies and reducing the systemic side effects of cancer vaccines.
View Article and Find Full Text PDFA multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues.
Lab Chip
June 2021
Department of Materials Science and Engineering, Research Institute of Advanced Materials (RIAM), Institute of Engineering Research, Bio-MAX Institute, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
Cancer immunotherapies based on the ability of T cells to recognize and kill tumor cells (TCs), including immune checkpoint blockade (ICB) therapy and chimeric antigen receptor (CAR) T cell therapy, have been greatly successful recently, but they are applicable for only a fraction of patients. One of the main challenges in cancer immunotherapy is the improvement of T cell infiltration into solid tumor tissues, as T cells can exert cytotoxicity against TCs only when they are in contact with TCs. T cells in the bloodstream infiltrate into solid tumor tissues by following two steps known as extravasation and interstitial migration.
View Article and Find Full Text PDF